Disclaimer

The website is targeted at investors qualifying as professional investors under MiFID (Directive 2004/39/EU) only. Retail investors are therefore kindly asked to leave this website.

The website and its content is not intended for US Persons, who are kindly asked to leave the website and visit CWorldWide.com/US/

By continuing to use the website, you confirm that you are a non-US person qualifying as a professional investor.

Choose your local website by clicking the globe in the right corner.

The content of the website is for information purposes only. The information does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any of the products or services mentioned on the website. The information, calculations, etc. on the website shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the information available through the website. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmaeglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions. Neither is C WorldWide Asset Management Fondsmaeglerselskab A/S responsible for the suitability of the information on or the content of the website. The information on the website may be amended by C WorldWide Asset Management Fondsmaeglerselskab A/S at any time without notice.

The website and its content has been prepared in accordance with Danish law and the information provided may not satisfy the laws of any other country.

INVESTMENT PHILOSOPHY

The investment objective of the C WorldWide Medical Small & Mid Cap fund is to achieve long-term capital growth by investing globally in a limited number of companies within healthcare. Investments are made in small and medium-sized companies in the pharmaceutical, biotechnology, medical technology, and healthcare sectors.

Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.

Our investment decisions are based on thorough, fundamental research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.